WA HB2613

Prohibits sale, transfer, or distribution of compounded drugs under federal Section 503A unless bulk drug substances comply with United States Pharmacopoeia standards, are components of FDA-approved drugs, or appear on the FDA's approved list for compounding

Requires compounders to verify bulk drug substances are pharmaceutical grade, accompanied by valid certificates of analysis identifying impurities and country of origin, and manufactured at FDA-registered establishments inspected within the last two years with satisfactory inspection ratings

Mandates quality control testing of bulk drug substances prior to use to confirm identity, content, and characterization of impurities

Imposes penalties of $1,000 per dose for illegally compounded drugs sold and revocation of pharmacy license for violations

Declares an emergency, taking effect immediately, citing concerns about foreign entities introducing contaminated or substandard active pharmaceutical ingredients into the supply chain, particularly for high-demand weight loss medications